

INTEGRA LIFESCIENCES HOLDINGS CORP
 Form 3
 May 05, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Coleman Glenn		(Month/Day/Year)	INTEGRA LIFESCIENCES HOLDINGS CORP [IART]	
(Last)	(First)	(Middle)	05/02/2014	
311 ENTERPRISE DRIVE			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
PLAINSBORO,Â NJÂ 08536			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			CVP, CHIEF FINANCIAL OFFICER	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Coleman Glenn 311 ENTERPRISE DRIVE PLAINSBORO, NJ 08536	^	^	^ CVP, CHIEF FINANCIAL OFFICER	^

Signatures

/s/ Richard Gorelick;
Attorney-in-Fact

05/05/2014

__Signature of Reporting Person

Date

Explanation of Responses:

No securities are beneficially owned

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. px;margin-bottom:0px" ALIGN="center">/s/ JOSEPH FESHBACH

Joseph Feshbach

Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to Registration Statement on Form S-3 has been signed by the following persons in the capacities indicated on the dates indicated.

Dated: August 19, 2003

By: /s/ JOSEPH FESHBACH

Joseph Feshbach

Chairman of the Board and

Chief Executive Officer

(Principal Executive Officer)

Dated: August 19, 2003

By: /s/ THOMAS AXMACHER

Thomas Axmacher

Chief Financial Officer

Edgar Filing: INTEGRA LIFESCIENCES HOLDINGS CORP - Form 3

(Principal Financial and Accounting Officer)

Dated: August 19, 2003

*

John C. Prior

President, Specialty Healthcare Services and Director

Dated: August 19, 2003

*

Paul S. Auerbach, MD

Director

Dated: August 19, 2003

*

Daniel E. Berce

Director

Dated: August 19, 2003

*

Lawrence English

Director

Dated: August 19, 2003

*

Gerard Moufflet

Director

Dated: August 19, 2003

*

Timothy I. Maudlin

Director

Dated: August 19, 2003

*By:

/s/ JOSEPH FESHBACH

Joseph Feshbach

Attorney-in-Fact

EXHIBIT INDEX

Exhibit	
Number	Description
2.1	Plan of Merger, dated as of August 15, 2003 by and among Curative Health Services, Inc., Curative Holding Co., and Curative Health Services Co. (incorporated by reference to Exhibit 2.1 on Form 8-K dated August 19, 2003, of Curative Health Services, Inc., the predecessor company).
3.1	Amended and Restated Articles of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the report filed by the Registrant on Form 8-K with the Commission on August 19, 2003).
3.2	Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the report filed by the Registrant on Form 8-K with the Commission on August 19, 2003).
3.3	Rights Agreement, dated as of October 25, 1995, between the Registrant and Wells Fargo Bank Minnesota, N.A. (incorporated by reference to Exhibit 4 of the report filed by Curative Health Services, Inc., the predecessor company, on Form 8-K with the Commission on November 8, 1995 (File No. 000-19370)).
5.1	Opinion of Dorsey & Whitney LLP (counsel to the Registrant) as to the legality of the securities being registered.
23.1	Consent of Ernst & Young LLP.
23.2	Consent of Dorsey & Whitney LLP (included in Exhibit 5.1).
24.1	Power of Attorney.